Clinical effectiveness of Liraglutide 3.0 mg and impact of weight loss in improving obesity-related comorbid conditions in King Fahad Medical City, Kingdom of Saudi Arabia: A real-world experience.

Obesity has emerged as one of the most challenging worldwide problems and, if left untreated, can lead to major illnesses and consequences that can impair patients' health The study's objective was to evaluate the effectiveness of Liraglutide 3.0 mg in inducing weight loss and to assess the improvement of obesity-related comorbid conditions among people living with obesity (PwO) in the Kingdom of Saudi Arabia (KSA). A retrospective cohort review of PwO with or without diabetes and taking Liraglutide 3.0 mg in combination with diet and exercise for weight management was performed and evaluated at King Fahad Medical City, Riyadh, KSA. We collected patient data from electronic medical records for different parameters. The side effects were not recorded. A cohort of 399 patients who used Liraglutide 3.0 mg for 6 months was included in the study. At baseline, the mean age of the cohort was 46.4 (±12.1) years, mean BMI was 40.4 (±7.7) kg/m 2 and most patients (74.4%) were women. Their mean average weight loss was 6.5 (±9.5) kg; p < .001. In the entire cohort, 52.6% of subjects had lost ≥5% of their bodyweight, 27.8% of subjects had lost ≥10%, and 11.3% of subjects had lost ≥15% of their bodyweight. There was a significant reduction in HbA1c by 0.5% (p < .0001) at 6 months of the treatment. Liraglutide 3.0 mg treatment did not affect systolic blood pressure and alanine transferase. Liraglutide 3.0 mg resulted in clinically significant weight loss with better glycaemic control, confirming the drug's effectiveness in the real-world evidence setting.